🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A

RecruitingPhase 1, Phase 2Ages 21 Years - 45 YearsMaleArditus Pte Ltd
NCT07787091 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is evaluating ARD001, an investigational medicine being developed for the treatment of hemophilia A. In Phase 1, healthy adult participants will receive a single dose of ARD001 or placebo to assess its safety and tolerability, how it moves through the body, its effects on blood coagulation, and whether the body develops antibodies against it. If the Phase 1 results support further study and the required regulatory and ethics approvals are obtained, Phase 2 will evaluate repeated doses of ARD001 in adults with hemophilia A. Phase 2 is not currently open for enrollment. The study is designed to determine whether ARD001 can be administered with acceptable safety and to identify doses suitable for further clinical development.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Phase 1 Inclusion Criteria: * Healthy adults within the specified age and body-weight ranges * Able and willing to provide informed consent * Considered healthy based on medical history, physical examination, vital signs, electrocardiogram and laboratory assessments * Other essential criteria from the approved protocol Phase 1 Exclusion Criteria: * History of severe drug or food allergy, or known allergy to ARD001 or its components * Acute infection within 14 days before dosing or fever on the planned dosing day * Clinically significant cardiovascular, coagulation, hepatic, renal or other medical abnormality * Recent use of prohibited medications within the protocol-defined washout periods * Other major exclusions from the approved protocol
💊

What it tests

  • ARD001
  • Placebo
📍

Where

1 site
SingHealth Investigational Medicine Unit
Singapore, Singapore
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy